Arvinas, Inc (ARVN) — Analysis Summary
Arvinas, Inc (ARVN) has a market cap of $549.24M with year-over-year revenue growth of -0.3%. Net margin stands at -30.8%. The stock trades at a P/E ratio of 59.1.
Key Takeaways
- Revenue changed -0.3% year-over-year
- Net margin of -30.8%
- P/E ratio of 59.1
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ARVN posted revenue growth of -0.3% and trades at a P/E of 59.1.
Arvinas, Inc (ARVN)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
The latest filing shows negative free cash flow.
Operating cash flow is negative while net income remains positive.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
246
Headquarters
NEW HAVEN, CT
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.